JP2017093436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017093436A5 JP2017093436A5 JP2016232150A JP2016232150A JP2017093436A5 JP 2017093436 A5 JP2017093436 A5 JP 2017093436A5 JP 2016232150 A JP2016232150 A JP 2016232150A JP 2016232150 A JP2016232150 A JP 2016232150A JP 2017093436 A5 JP2017093436 A5 JP 2017093436A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- nucleic acid
- water
- lipid component
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 21
- 150000002632 lipids Chemical class 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- -1 cationic lipid Chemical class 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- 229940063675 spermine Drugs 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims 1
- 239000005700 Putrescine Substances 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161443246P | 2011-02-15 | 2011-02-15 | |
| US61/443,246 | 2011-02-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Division JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017093436A JP2017093436A (ja) | 2017-06-01 |
| JP2017093436A5 true JP2017093436A5 (cg-RX-API-DMAC7.html) | 2017-09-14 |
| JP6313406B2 JP6313406B2 (ja) | 2018-04-18 |
Family
ID=46673165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Expired - Fee Related JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
| JP2016232150A Active JP6313406B2 (ja) | 2011-02-15 | 2016-11-30 | 核酸を細胞へ送達する組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553671A Expired - Fee Related JP6054308B2 (ja) | 2011-02-15 | 2012-02-15 | 核酸を細胞へ送達する組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20140065204A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2675918B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6054308B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012217685B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2827118A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012112730A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| ITRM20120480A1 (it) * | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| RS66380B1 (sr) | 2014-04-23 | 2025-02-28 | Modernatx Inc | Vakcine nukleinske kiseline |
| EP3166622B1 (en) | 2014-07-08 | 2019-10-23 | The Children's Medical Center Corporation | Compositions and methods for treating diabetes |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| EP4212148A1 (en) | 2015-05-26 | 2023-07-19 | Plumb Pharmaceuticals, Inc. | Liposome loading |
| AU2016309002B2 (en) | 2015-08-20 | 2021-07-29 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment |
| HK1257220A1 (zh) | 2015-08-21 | 2019-10-18 | 益普生生物制药有限公司 | 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法 |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| SG10202104058XA (en) | 2015-10-14 | 2021-05-28 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
| RS67289B1 (sr) | 2015-10-16 | 2025-11-28 | Ipsen Biopharm Ltd | Stabilizacija farmaceutskih kompozicija kamptotecina |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| EP4036079B1 (en) | 2015-12-22 | 2025-11-19 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| MX2019003070A (es) | 2016-09-16 | 2019-10-14 | Bio Path Holdings Inc | Terapia de combinacion con oligonucleotidos antisentido liposomales. |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| EP3604269A4 (en) * | 2017-03-29 | 2021-01-27 | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences | APPLICATION OF A COMPOUND OR AN EXTRACT OF TRADITIONAL CHINESE MEDICINE IN THE PREPARATION OF A NUCLEIC ACID ADMINISTRATION AGENT AND RELATED MATERIALS |
| IL269608B2 (en) | 2017-04-19 | 2024-06-01 | Bio Path Holdings Inc | Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease |
| EP3612160A4 (en) | 2017-04-19 | 2021-01-20 | Bio-Path Holdings, Inc. | P-ETHOXY NUCLEIC ACIDS TO INHIBIT BCL2 |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| JP6462073B1 (ja) * | 2017-09-04 | 2019-01-30 | 一丸ファルコス株式会社 | ｐＨ感受性リポソームの製造方法 |
| KR20250024524A (ko) | 2017-10-20 | 2025-02-18 | 비온테크 에스이 | 치료법에 적합한 리포조말 rna 제형의 제조 및 저장 |
| US20210100905A1 (en) * | 2018-03-29 | 2021-04-08 | Institute Of Basic Medical Sciences Chinese Academy Of Medicalsciences | Application of compound or traditional chinese medicine extract in preparation of nucleic acid delivery agent, and related products |
| EP3789043A4 (en) * | 2018-03-29 | 2022-08-03 | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences | EXTRACTION OF "MEDICINAL SOUP" FROM PLANT SOURCE AND MANUAL PREPARATION OF "MEDICINAL PLANT" AND ASSOCIATED PRODUCTS |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061457A1 (en) * | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US11197827B2 (en) | 2018-10-31 | 2021-12-14 | Microsoft Technology Licensing, Llc | Polynucleotide encapsulation and preservation using self-assembling membranes |
| WO2020200472A1 (en) | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
| AR120080A1 (es) | 2019-09-19 | 2022-02-02 | Modernatx Inc | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CA3195019A1 (en) | 2020-10-06 | 2022-04-14 | Maria Fardis | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| TW202327631A (zh) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者 |
| EP4423755A2 (en) | 2021-10-27 | 2024-09-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| JP2024544867A (ja) | 2021-11-10 | 2024-12-05 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｃｄ８腫瘍浸潤リンパ球を利用する拡張治療の方法 |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| CN114984236B (zh) * | 2022-04-29 | 2023-03-24 | 深圳近邻生物科技有限公司 | 一种响应型核酸递送系统及其制备方法、交联聚合物载体 |
| WO2025108545A1 (en) * | 2023-11-22 | 2025-05-30 | Danmarks Tekniske Universitet | Delivery of nucleotides from injectable biomaterial |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908635A (en) * | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6794128B2 (en) | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US7780882B2 (en) * | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
| EP1694298B1 (en) * | 2003-11-03 | 2010-06-09 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same |
| JP4651276B2 (ja) * | 2003-11-12 | 2011-03-16 | テルモ株式会社 | リポソームを体内より排泄する抗体およびリポソームの血中クリアランス促進剤 |
| JP3941808B2 (ja) | 2004-10-28 | 2007-07-04 | 株式会社日立製作所 | 動画像の変化点検出方法及び装置 |
| US20070171077A1 (en) | 2006-01-26 | 2007-07-26 | Behrouz Kawarizadeh | License Plate Incorporating RFID Device |
| JP5334170B2 (ja) * | 2007-02-09 | 2013-11-06 | 国立大学法人 奈良先端科学技術大学院大学 | Ｃ７０含有リポソームおよびその製造方法、並びにその利用 |
| DK2129396T3 (da) | 2007-02-16 | 2013-11-25 | Merrimack Pharmaceuticals Inc | Antistoffer mod ErbB3 og anvendelser deraf |
| CA2702103A1 (en) | 2007-10-12 | 2009-04-16 | Novosom Ag | Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| WO2009061515A1 (en) * | 2007-11-09 | 2009-05-14 | Northeastern University | Self-assembling micelle-like nanoparticles for systemic gene delivery |
| US20100112042A1 (en) * | 2008-10-16 | 2010-05-06 | Mdrna, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
| JP5532635B2 (ja) * | 2009-03-11 | 2014-06-25 | 凸版印刷株式会社 | 核酸含有リポソームを用いた遺伝子解析方法及び遺伝子解析キット |
| EP2623117A1 (en) | 2009-04-30 | 2013-08-07 | Genetic Immunity Kft. | Immunogenic nanomedicine composition and preparation and uses thereof |
| US8420118B2 (en) * | 2009-09-10 | 2013-04-16 | The Board Of Regents Of The University Of Oklahoma | Anionic lipids and lipid nano-structures and methods of producing and using same |
-
2012
- 2012-02-15 JP JP2013553671A patent/JP6054308B2/ja not_active Expired - Fee Related
- 2012-02-15 CA CA2827118A patent/CA2827118A1/en not_active Abandoned
- 2012-02-15 AU AU2012217685A patent/AU2012217685B2/en not_active Ceased
- 2012-02-15 WO PCT/US2012/025324 patent/WO2012112730A2/en not_active Ceased
- 2012-02-15 EP EP12746634.0A patent/EP2675918B1/en not_active Not-in-force
-
2013
- 2013-08-15 US US13/967,664 patent/US20140065204A1/en not_active Abandoned
-
2016
- 2016-01-22 US US15/004,481 patent/US10087464B2/en not_active Expired - Fee Related
- 2016-11-30 JP JP2016232150A patent/JP6313406B2/ja active Active
-
2018
- 2018-07-02 US US16/025,503 patent/US20190017073A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017093436A5 (cg-RX-API-DMAC7.html) | ||
| JP7496808B2 (ja) | リポカチオン性デンドリマーおよびその使用 | |
| JP7480220B2 (ja) | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 | |
| AU2016385135B2 (en) | Bifurcating mixers and methods of their use and manufacture | |
| JP6313406B2 (ja) | 核酸を細胞へ送達する組成物及び方法 | |
| CN105939699B (zh) | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 | |
| JP2012526858A5 (cg-RX-API-DMAC7.html) | ||
| JP2010184947A5 (cg-RX-API-DMAC7.html) | ||
| JP2019508371A5 (cg-RX-API-DMAC7.html) | ||
| CA2935914C (en) | Cationic lipid | |
| CA2748520A1 (en) | Pharmaceutical composition containing an anionic drug, and a production method therefor | |
| CN107028886A (zh) | 含有核酸的脂质粒子及相关的方法 | |
| David et al. | siRNA LNCs–a novel platform of lipid nanocapsules for systemic siRNA administration | |
| CN108366964A (zh) | 制备含阴离子药物的聚合物胶束的方法 | |
| JP2012532839A5 (cg-RX-API-DMAC7.html) | ||
| WO2010142660A2 (en) | Drug delivery system | |
| CN101646443B (zh) | 速效型核酸转运用载体组合物 | |
| Kocsis et al. | Supramolecular rulers enabling selective detection of pure short ssDNA via chiral self-assembly | |
| CN118750468A (zh) | 一种核酸-脂质纳米颗粒冻干组合物及其制备方法和应用 | |
| WO2025011380A1 (zh) | 脂质化合物、组合物及其制备方法和应用 | |
| JP5808246B2 (ja) | 核酸複合体、及び核酸送達用組成物 | |
| CN119913209A (zh) | 一种用于向细胞内递送核酸的组合物 | |
| US20250319035A1 (en) | Cationic lipid nanoparticle having high transfection efficiency and preparation method therefor | |
| CN121197094A (zh) | 一种花生四烯酸脂质纳米递药系统 | |
| Khader et al. | Optimizing Hydrophobic Chain Length in Cardanol‐Based Quaternary Ammonium Compounds Enhances Gene Delivery Efficiency |